{"title":"日本皮肤病协会指南:2025年黑色素瘤指南的临床问题。","authors":"Satoshi Fukushima, Takamichi Ito, Jun Asai, Hiroshi Igaki, Ryota Tanaka, Kenjiro Namikawa, Ayato Hayashi, Akane Minagawa, Takuya Miyagawa, Azusa Miyashita, Dai Ogata, Mao Okumura, Yukiko Kiniwa, Hiroyuki Goto, Takeshi Namiki, Hiroki Hashimoto, Tokimasa Hida, Takero Hirata, Taku Maeda, Takamitsu Matsuzawa, Teruki Yanagi, Kanae Sugimoto, Emi Kimura, Hiroshi Koga, Hiroshi Uchi, Tomomitsu Miyagaki, Yasuhiro Nakamura, Takashi Inozume","doi":"10.1111/1346-8138.17740","DOIUrl":null,"url":null,"abstract":"<p>Advancements in melanoma management have underscored the need for periodic guideline updates every few years to reflect current clinical practices. Previous versions of melanoma clinical practice guidelines in Japan have primarily aimed to reflect global standards of care. This focus on international benchmarks was largely attributed to the scarcity of high-quality evidence from East Asia, necessitating reliance on Western references. Recent findings indicate differences in melanoma subtypes and drug efficacy between Western and East Asian populations. Therefore, efforts were made to incorporate data from East Asia in this revision, aiming to develop guidelines that better reflect the region's unique characteristics. This revision was commissioned by the Japanese Dermatological Association (JDA) and Japanese Skin Cancer Society (JSCS) and was undertaken by a committee comprising experts across relevant fields who meticulously reviewed and systematized a wide range of literature on melanoma to develop comprehensive, evidence-based guidelines. Literature searches were conducted by the Japan Medical Library Association. The recommendation statements were determined using the GRADE Grid approach. The guideline was developed in accordance with the Minds Clinical Practice Guideline Creation Manual 2020, ver. 3.0. Twelve clinical questions (CQs) were established, and corresponding recommendation statements were provided for each CQ. For several CQs, the inclusion of data from East Asia resulted in recommendations that differed from those in Western guidelines. Considering that the biology of melanoma has been increasingly recognized to vary by subtype and ethnicity, guidelines should be developed independently for each region based on evidence specific to the melanoma characteristics of that region. We firmly believe that this Japanese clinical guideline for melanoma will contribute to improving melanoma management in East Asia.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 8","pages":"e666-e697"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17740","citationCount":"0","resultStr":"{\"title\":\"Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Melanoma 2025\",\"authors\":\"Satoshi Fukushima, Takamichi Ito, Jun Asai, Hiroshi Igaki, Ryota Tanaka, Kenjiro Namikawa, Ayato Hayashi, Akane Minagawa, Takuya Miyagawa, Azusa Miyashita, Dai Ogata, Mao Okumura, Yukiko Kiniwa, Hiroyuki Goto, Takeshi Namiki, Hiroki Hashimoto, Tokimasa Hida, Takero Hirata, Taku Maeda, Takamitsu Matsuzawa, Teruki Yanagi, Kanae Sugimoto, Emi Kimura, Hiroshi Koga, Hiroshi Uchi, Tomomitsu Miyagaki, Yasuhiro Nakamura, Takashi Inozume\",\"doi\":\"10.1111/1346-8138.17740\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Advancements in melanoma management have underscored the need for periodic guideline updates every few years to reflect current clinical practices. Previous versions of melanoma clinical practice guidelines in Japan have primarily aimed to reflect global standards of care. This focus on international benchmarks was largely attributed to the scarcity of high-quality evidence from East Asia, necessitating reliance on Western references. Recent findings indicate differences in melanoma subtypes and drug efficacy between Western and East Asian populations. Therefore, efforts were made to incorporate data from East Asia in this revision, aiming to develop guidelines that better reflect the region's unique characteristics. This revision was commissioned by the Japanese Dermatological Association (JDA) and Japanese Skin Cancer Society (JSCS) and was undertaken by a committee comprising experts across relevant fields who meticulously reviewed and systematized a wide range of literature on melanoma to develop comprehensive, evidence-based guidelines. Literature searches were conducted by the Japan Medical Library Association. The recommendation statements were determined using the GRADE Grid approach. The guideline was developed in accordance with the Minds Clinical Practice Guideline Creation Manual 2020, ver. 3.0. Twelve clinical questions (CQs) were established, and corresponding recommendation statements were provided for each CQ. For several CQs, the inclusion of data from East Asia resulted in recommendations that differed from those in Western guidelines. Considering that the biology of melanoma has been increasingly recognized to vary by subtype and ethnicity, guidelines should be developed independently for each region based on evidence specific to the melanoma characteristics of that region. We firmly believe that this Japanese clinical guideline for melanoma will contribute to improving melanoma management in East Asia.</p>\",\"PeriodicalId\":54848,\"journal\":{\"name\":\"Journal of Dermatology\",\"volume\":\"52 8\",\"pages\":\"e666-e697\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17740\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.17740\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.17740","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Melanoma 2025
Advancements in melanoma management have underscored the need for periodic guideline updates every few years to reflect current clinical practices. Previous versions of melanoma clinical practice guidelines in Japan have primarily aimed to reflect global standards of care. This focus on international benchmarks was largely attributed to the scarcity of high-quality evidence from East Asia, necessitating reliance on Western references. Recent findings indicate differences in melanoma subtypes and drug efficacy between Western and East Asian populations. Therefore, efforts were made to incorporate data from East Asia in this revision, aiming to develop guidelines that better reflect the region's unique characteristics. This revision was commissioned by the Japanese Dermatological Association (JDA) and Japanese Skin Cancer Society (JSCS) and was undertaken by a committee comprising experts across relevant fields who meticulously reviewed and systematized a wide range of literature on melanoma to develop comprehensive, evidence-based guidelines. Literature searches were conducted by the Japan Medical Library Association. The recommendation statements were determined using the GRADE Grid approach. The guideline was developed in accordance with the Minds Clinical Practice Guideline Creation Manual 2020, ver. 3.0. Twelve clinical questions (CQs) were established, and corresponding recommendation statements were provided for each CQ. For several CQs, the inclusion of data from East Asia resulted in recommendations that differed from those in Western guidelines. Considering that the biology of melanoma has been increasingly recognized to vary by subtype and ethnicity, guidelines should be developed independently for each region based on evidence specific to the melanoma characteristics of that region. We firmly believe that this Japanese clinical guideline for melanoma will contribute to improving melanoma management in East Asia.
期刊介绍:
The Journal of Dermatology is the official peer-reviewed publication of the Japanese Dermatological Association and the Asian Dermatological Association. The journal aims to provide a forum for the exchange of information about new and significant research in dermatology and to promote the discipline of dermatology in Japan and throughout the world. Research articles are supplemented by reviews, theoretical articles, special features, commentaries, book reviews and proceedings of workshops and conferences.
Preliminary or short reports and letters to the editor of two printed pages or less will be published as soon as possible. Papers in all fields of dermatology will be considered.